The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells

Mantle cell lymphoma (MCL) accounts for 5%–10% of all lymphomas. The disease’s genetic hallmark is the t(11; 14)(q13; q32) translocation. In younger patients, the first-line treatment is chemoimmunotherapy followed by autologous stem cell transplantation. Upon disease progression, novel and targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Bewarder, Moritz, Kiefer, Maximilian, Will, Helene, Olesch, Kathrin, Moelle, Clara, Stilgenbauer, Stephan, Christofyllakis, Konstantinos, Kaddu-Mulindwa, Dominic, Bittenbring, Joerg Thomas, Fadle, Natalie, Regitz, Evi, Kaschek, Lea, Hoth, Markus, Neumann, Frank, Preuss, Klaus-Dieter, Pfreundschuh, Michael, Thurner, Lorenz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274796/
https://www.ncbi.nlm.nih.gov/pubmed/34263144
http://dx.doi.org/10.1097/HS9.0000000000000620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274796/
https://www.ncbi.nlm.nih.gov/pubmed/34263144
http://dx.doi.org/10.1097/HS9.0000000000000620

Ejemplares similares